Search

Author/Creator Jensen, E

1. 901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. (23rd October 2018)

Authors:
Bellmunt, J; de Wit, R; Vaughn, D J; Fradet, Y; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D; Choueiri, T K; Necchi, A; Gerritsen, W R; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Jensen, E; Frenkl, T; Perini, R F; Bajorin, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (31st January 2019)

Authors:
Hamid, O; Robert, C; Daud, A; Hodi, F S; Hwu, W J; Kefford, R; Wolchok, J D; Hersey, P; Joseph, R; Weber, J S; Dronca, R; Mitchell, T C; Patnaik, A; Zarour, H M; Joshua, A M; Zhao, Q; Jensen, E; Ahsan, S; Ibrahim, N; Ribas, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
582
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. (17th December 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. PERLE. Powerful energy recovery linac for experiments. Conceptual design report. (3rd May 2018)

Authors:
Angal-Kalinin, D; Arduini, G; Auchmann, B; Bernauer, J; Bogacz, A; Bordry, F; Bousson, S; Bracco, C; Brüning, O; Calaga, R; Cassou, K; Chetvertkova, V; Cormier, E; Daly, E; Douglas, D; Dupraz, K; Goddard, B; Henry, J; Hutton, A; Jensen, E
Journal:
Journal of physics
Issue:
Volume 45:Number 6(2018:Jun.)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗